Exelixis's SWOT analysis: cancer drug maker's stock faces patent cliff, pipeline promise
Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...
Wall Street Journal14d
Sonida Senior Living Corp.
1 Day SNDA -1.84% DJIA -0.32% Russell 2K -0.30% Health Care/Life Sciences -0.52% ...
London South East15d
Sunda Energy Share Chat (SNDA)
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
Top17d
KCET Registration 2025: Important Dates, Application Process and Key Details
The KEA will provide regular updates and notifications on its official website. Aspirants are encouraged to stay proactive, regularly check the site, and complete the application process well before ...
Top17d
UPSC CSE Notification 2025: Exam Dates, Application Process and Key Details You Need to Know
The UPSC's decision to advance the 2025 CSE notification underscores its commitment to enhancing the exam process. With the prelims scheduled for May and the mains in August, aspirants have a clear ...
Seeking Alpha18d
J&J wins label expansion for depression therapy Spravato
Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine), expanding its use as a single agent ...
Business Insider18d
JNJ's SNDA For Spravato Monotherapy Gets FDA Approval For Treatment-Resistant Depression
(RTTNews) - Johnson & Johnson (JNJ), Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with ...
Yahoo Finance18d
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA ...
Business Insider18d
Johnson & Johnson announces FDA approves sNDA for Spravato
Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this innovative treatment the first and only monotherapy for adults ...
Independent Online18d
Durban University of Technology says walk-in student applications not allowed
The Durban University of Technology (DUT) has reiterated that it does not permit walk-in applications for the 2025 academic year. The institution has emphasised that its application deadline ...
Contract Pharma18d
Johnson & Johnson’s SPRAVATO Approved as Standalone Treatment for MDD
The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Johnson & Johnson’s SPRAVATO (esketamine) CIII nasal spray, making the treatment the first and ...